Related Experiment Video
Updated: Jun 15, 2026
15:09
The Use of Primary Human Fibroblasts for Monitoring Mitochondrial Phenotypes in the Field of Parkinson's Disease
Published on: October 3, 2012
Mitochondrial therapies for Parkinson's disease
1Department of Neurology and Neuroscience, Weill Medical College of Cornell University, New York, New York 10065, USA. bot2003@med.cornell.edu
Movement Disorders : Official Journal of the Movement Disorder Society
|February 27, 2010
Summary
Mitochondrial dysfunction is central to Parkinson's disease (PD) pathogenesis. Therapies targeting mitochondrial preservation offer promising neuroprotection for PD.
Area of Science:
- Neuroscience
- Mitochondrial Biology
- Pharmacology
Background:
- Parkinson's disease (PD) involves neurodegeneration, particularly dopaminergic neuron loss.
- Mitochondrial dysfunction is a key factor in both sporadic and familial PD.
- Impaired mitochondrial functions contribute to central nervous system (CNS) dysfunction and neurodegeneration.
Purpose of the Study:
- To review drugs targeting mitochondrial dysfunction in PD.
- To explore novel mitochondrial survival pathways for neuroprotection in PD.
Main Methods:
- Literature review of experimental models and clinical trials for PD drugs.
- Analysis of research on mitochondrial pathways relevant to PD.
Main Results:
- Several drugs show potential in blocking mitochondrial dysfunction in PD models.
- Clinical trials are evaluating some of these drugs for PD treatment.
- Novel pathways for mitochondrial survival are emerging as therapeutic targets.
Conclusions:
- Preserving mitochondrial function is a critical therapeutic strategy for PD.
- Investigating drugs and pathways that support mitochondrial health holds promise for future PD treatments.
Related Concept Videos
01:24Parkinson's Disease: Treatment
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
01:15Parkinson's Disease: Overview
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
01:46Electron Transport Chain: Complex I and II
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
ROS generation is regulated and maintained at moderate levels necessary...
01:24Parkinson Disease ll: Pathophysiology
Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
01:24Parkinson Disease l: Introduction
Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...
01:37Mitochondria
Mitochondria are eukaryotic cellular organelles that are known to produce energy through a process called oxidative phosphorylation. Besides their primary function, mitochondria are involved in various cellular processes, including cell growth, differentiation, signaling, metabolism, and senescence. Age-related changes cause a decline in mitochondrial quality and integrity due to increased mitochondrial mutations and oxidative damage. Thus, aging can severely impact mitochondrial functions,...